Literature DB >> 18806759

E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35.

G Merdzhanova1, V Edmond, S De Seranno, A Van den Broeck, L Corcos, C Brambilla, E Brambilla, S Gazzeri, B Eymin.   

Abstract

The transcription factor E2F1 has a key function during S phase progression and apoptosis. It has been well-demonstrated that the apoptotic function of E2F1 involves its ability to transactivate pro-apoptotic target genes. Alternative splicing of pre-mRNAs also has an important function in the regulation of apoptosis. In this study, we identify the splicing factor SC35, a member of the Ser-Rich Arg (SR) proteins family, as a new transcriptional target of E2F1. We demonstrate that E2F1 requires SC35 to switch the alternative splicing profile of various apoptotic genes such as c-flip, caspases-8 and -9 and Bcl-x, towards the expression of pro-apoptotic splice variants. Finally, we provide evidence that E2F1 upregulates SC35 in response to DNA-damaging agents and show that SC35 is required for apoptosis in response to these drugs. Taken together, these results demonstrate that E2F1 controls pre-mRNA processing events to induce apoptosis and identify the SC35 SR protein as a key direct E2F1-target in this setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806759     DOI: 10.1038/cdd.2008.135

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  57 in total

1.  Ontogenomic study of the relationship between number of gene splice variants and GO categorization.

Authors:  Ari B Kahn; Barry R Zeeberg; Michael C Ryan; D Curtis Jamison; David M Rockoff; Yves Pommier; John N Weinstein
Journal:  Bioinformatics       Date:  2010-07-08       Impact factor: 6.937

2.  Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin.

Authors:  Valerie Edmond; Elodie Moysan; Saadi Khochbin; Patrick Matthias; Christian Brambilla; Elisabeth Brambilla; Sylvie Gazzeri; Beatrice Eymin
Journal:  EMBO J       Date:  2010-12-14       Impact factor: 11.598

Review 3.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

4.  Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells.

Authors:  Sanjai Sharma; Alan Lichtenstein
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

5.  SKIP counteracts p53-mediated apoptosis via selective regulation of p21Cip1 mRNA splicing.

Authors:  Yupeng Chen; Lirong Zhang; Katherine A Jones
Journal:  Genes Dev       Date:  2011-04-01       Impact factor: 11.361

6.  Methylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional Mechanisms.

Authors:  Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal:  J Biol Chem       Date:  2015-03-28       Impact factor: 5.157

7.  Group VIA Phospholipase A2 (iPLA2β) Modulates Bcl-x 5'-Splice Site Selection and Suppresses Anti-apoptotic Bcl-x(L) in β-Cells.

Authors:  Suzanne E Barbour; Phuong T Nguyen; Margaret Park; Bhargavi Emani; Xiaoyong Lei; Mamatha Kambalapalli; Jacqueline C Shultz; Dayanjan Wijesinghe; Charles E Chalfant; Sasanka Ramanadham
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

8.  Emetine regulates the alternative splicing of caspase 9 in tumor cells.

Authors:  Danmin Pan; Kritsanapol Boon-Unge; Piyarat Govitrapong; Jianhua Zhou
Journal:  Oncol Lett       Date:  2011-08-29       Impact factor: 2.967

9.  Large-scale evidence for conservation of NMD candidature across mammals.

Authors:  David A de Lima Morais; Paul M Harrison
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

10.  Antagonistic factors control the unproductive splicing of SC35 terminal intron.

Authors:  Natacha Dreumont; Sara Hardy; Isabelle Behm-Ansmant; Liliane Kister; Christiane Branlant; James Stévenin; Cyril F Bourgeois
Journal:  Nucleic Acids Res       Date:  2009-12-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.